The about-$1 billion deal could come imminently.

Schrodinger said on Friday it is collaborating with Eli Lilly to offer the pharmaceutical major's AI-based platform, TuneLab, ...

An approval of Lilly's pill, along with its current strength in the weight loss market, could equal revenue growth well into ...

Eli Lilly and Company (NYSE:LLY) is one of the best performing pharma stocks in 2025. Eli Lilly and Company (NYSE:LLY) ...

Eli Lilly said Thursday that adding its weight loss drug Zepbound on top of its immunology therapy Taltz helped obese ...

Eli Lilly is considering all these risks and planning accordingly, and doing so years in advance. That's also why the ...

Eli Lilly has the lead in the GLP-1 race, but Novo Nordisk just changed the game.

Schrödinger (SDGR) and Revvity (RVTY) on Friday announced collaborations with Eli Lilly (LLY) to integrate their respective ...

Eli Lilly and Company rated Buy: incretin/obesity growth, ZEPBOUND & orforglipron access strategy, pipeline deals, ...

FDA oral Wegovy, solid fundamentals, and low P/E vs. Eli Lilly. Click for this updated look at NVO stock prospects as ...

Eli Lilly has doubled its investment in its new Concord manufacturing facility from $1 billion to $2 billion since construction began in 2022, the company confirmed. The pharmaceutical giant hosted a ...

(Editor’s note: This story was written before Eli Manning was not included in the Pro Football Hall of Fame class of 2025.) Two guys are sitting in a bar. They could be talking about who the Giants’ ...